Navigation Links
Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
Date:1/6/2009

SEATTLE, Jan. 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has received notification that the NASDAQ Listing Qualifications Panel has granted CTI's request to transfer the listing of its common stock from The NASDAQ Global Market to The NASDAQ Capital Market, which will be effective with the open of trading on Thursday, January 8, 2009. CTI's shares will continue to trade under the ticker symbol CTIC.

CTI's continued listing on The NASDAQ Capital Market is subject to CTI evidencing compliance with all applicable requirements for continued listing on The NASDAQ Capital Market, including the $35 million market value of listed securities requirement or its alternatives, as set forth in NASDAQ Marketplace Rule 4310(c)(3), by February 12, 2009. The Company expects to comply with all applicable requirements for continued listing on The NASDAQ Capital Market by February 12, 2009; however, there can be no assurance that it will be able to do so.

As disclosed on September 6 and October 10, 2008, CTI was previously notified by NASDAQ regarding its non-compliance with the $50 million market value of listed securities requirement for continued listing on The NASDAQ Global Market. In response, CTI appeared before the NASDAQ Listing Qualifications Panel at a hearing at which it requested the transfer of its listing to The NASDAQ Capital Market pursuant to its plan to evidence compliance with the $35 million market value of listed securities requirement for continued listing on that market.

The NASDAQ Capital Market is one of the three market tier designations for NASDAQ-listed stocks and operates in substantially the same manner as The NASDAQ Global Market. Securities listed on The NASDAQ Capital Market must satisfy all applicable qualification requirements for NASDAQ securities, and companies listed on The NASDAQ Capital Market must meet certai
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Horizon Therapeutics Announces Senior Management Appointments
2. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
3. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
4. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
5. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
6. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
7. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
8. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
9. FDA Accepts Cell Therapeutics Zevalin sBLA and Grants Priority Review
10. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
11. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...NCLINE VILLAGE, Nev., Dec. 1 /PRNewswire-FirstCall...day announced revenue guidance for the fourth quar...illion, as compared with $69 million for the fourt... results was the first of two installment payments...fourth quarter 2008 results was a one-time $1.8 mi...
(Date:12/1/2009)... , NEW YORK, Dec. 1 Reportlinke...is available in its catalogue: ,, Industrial E....reportlinker.com/p0164431/Industrial-Enzymes---A-...s market is an oligopoly with few strong players a...et activities. Keen competition and commoditizatio...
(Date:12/1/2009)...PLYMOUTH, Mass., Dec. 1 Harvest Te... today results from the company sponsored 60-patie...ical Center in Chennai, India using the company,s ...able Critical Limb Ischemia (CLI). Sri Ramachandra...-associated institution based in Chennai, India an...
(Date:12/1/2009)..., Former Majority Leader Richard Gephardt Bring...ine, Biotech Communities for "Best and Brightest ...N.J., Dec. 1 Several of...euticals, research, medicine and technology gather...the importance of medical innovation in New Jersey...
Breaking Biology Technology:PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Reportlinker Adds Industrial Enzymes - A Global Market Report 2Reportlinker Adds Industrial Enzymes - A Global Market Report 3Reportlinker Adds Industrial Enzymes - A Global Market Report 4Reportlinker Adds Industrial Enzymes - A Global Market Report 5Reportlinker Adds Industrial Enzymes - A Global Market Report 6Reportlinker Adds Industrial Enzymes - A Global Market Report 7Reportlinker Adds Industrial Enzymes - A Global Market Report 8Reportlinker Adds Industrial Enzymes - A Global Market Report 9Reportlinker Adds Industrial Enzymes - A Global Market Report 10Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 2New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 3New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 4New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 5
...on Andy, Holder Completes First Year Inspiring Oth... Conditions, VALLEY FORGE, Pa., Jan. 17 In 2007...ppe(R), teamed up with "Iron Andy" Holder,as part ...campaign. Andy,set out to speak about living with ... resonated with dozens of individuals who were ins...
...ISON, N.J., Jan. 17 Wyeth Consumer Healthcare, a,...U.S. Food and Drug,Administration,s (FDA) decision...ugh and cold products in children under age two., ...emoval in October 2007,of over-the-counter infant ...help reduce dosing errors and overdoses in childre...
...or Advancement Towards Creating Patient-Specific a... For Therapeutic Use, LA JOLLA, Calif., Jan. 17 ...earch company, announced today it has become the,f...ment, a cloned human,embryo using somatic cell nuc...d, M.D., Ph.D., a co-author of the,publication and...
Other Biology Technology:Good Neighbor Pharmacy(R) Ironman Competitor Inspires Individuals with Diabetes to Live Without Limits 2Good Neighbor Pharmacy(R) Ironman Competitor Inspires Individuals with Diabetes to Live Without Limits 3Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age 2Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age 3Stemagen First to Create Cloned Human Embryos From Adult Cells 2Stemagen First to Create Cloned Human Embryos From Adult Cells 3
(Date:12/1/2009)...r 1, 2009: OptiNose is pleased to announce the pub...dy investigating the efficacy and tolerability of ...topical treatment of chronic rhinosinusitis with n...f the International and European Rhinologic Societ... is a chronic disease that can significantly reduc...
(Date:12/1/2009)...eorgia Institute of Technology has been awarded a ...structures for energy harvesting and adaptive mate...ognitive processes of the modern warfighter. , ...abled Inorganic/Organic Nanostructures and Improve...mir Tsukruk and Kenneth Sandhage, professors in Ge...
(Date:12/1/2009)...rld first, a Monash University-led international r...ost the output of the next generation of solar cel...oration with colleagues from the universities of W... dye-sensitised solar cells with a three-fold incr... previously reported tandem dye-sensitised solar c...
Breaking Biology News(10 mins):New data on highly effective treatment for chronic rhinosinusitis with nasal polyps 2Air Force Center of Excellence awarded in nanostructures and improved cognition 2Air Force Center of Excellence awarded in nanostructures and improved cognition 3Air Force Center of Excellence awarded in nanostructures and improved cognition 4Innovation puts next-generation solar cells on the horizon 2Journal of Midwifery 26amp 3B Womens Health honors outstanding authors 54619 1Journal of Midwifery 26amp 3B Womens Health honors outstanding authors 54619 2Imagenetix Inc Announces Interview With Bloomberg Radio 13589 1Imagenetix Inc Announces Interview With Bloomberg Radio 13589 2Real World Study Showed Cost Savings for VTE Prophylaxis with Enoxaparin Compared with Unfractionated Heparin 28UFH 29 4856 1Real World Study Showed Cost Savings for VTE Prophylaxis with Enoxaparin Compared with Unfractionated Heparin 28UFH 29 4856 2Real World Study Showed Cost Savings for VTE Prophylaxis with Enoxaparin Compared with Unfractionated Heparin 28UFH 29 4856 3Real World Study Showed Cost Savings for VTE Prophylaxis with Enoxaparin Compared with Unfractionated Heparin 28UFH 29 4856 4
..., Ohio (April 21, 2008) The technique lizards use...rding to researchers at Ohio University. , A res...acked 18 different species of lizards as they walk...g styles impact their biomechanics. The study, fun...ed in the April 1 edition of the Journal of Experi...
...urg, Va. Researchers from the Virginia Bioinforma...lleagues have identified a key function of a large...nt role in the production of infectious disease by...ofessor Brett Tyler and members of his research gr...partment of Plant Pathology, Physiology and Weed S...
...E #1 FOR IMMEDIATE RELEASE , Gel-like material... Biomacromolecules , Researchers in Texas report...p speed the long-awaited arrival of insulin that c...njections. The study is scheduled for the April 14.... , In the report, Nicholas A. Peppas and colleag...
Other Biology News:Lizard hunting styles impact ability to walk, run 2American Chemical Society's Weekly PressPac -- April 16, 2008 2American Chemical Society's Weekly PressPac -- April 16, 2008 3American Chemical Society's Weekly PressPac -- April 16, 2008 4American Chemical Society's Weekly PressPac -- April 16, 2008 5American Chemical Society's Weekly PressPac -- April 16, 2008 6American Chemical Society's Weekly PressPac -- April 16, 2008 7American Chemical Society's Weekly PressPac -- April 16, 2008 8
... Label IT siRNA Tracker Intracellular Localization...tly label and deliver siRNA, of your design, in an...o tracking experiments. Subcellular localization a... can be monitored following introduction of the la...
... Label IT siRNA Tracker Intracellular Localization...vides a straight forward approach to directly labe...nt yet non-destructive manner, for in vitro tracki...ional inhibition of target gene expression can be ...
...s kit allows for quick and reproducible immunoprec...e system is more reproducible than regular IPs, wh...otein A/G agarose without disrupting the agarose b... Catch and Release is reversible, and elution of t...
... Yeast Oligo Microarray Kit (V2), 2 x 11K will ena...ression of many thousands of yeast genes and ident...esses. Each microarray contains sequences represen... S288C strain of Saccharomyces cerevisiae, sourced...
Biology Products: